Silence Therapeutics plc

Silence Therapeutics plc is a biotechnology company focused on discovering and developing novel molecules that use short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes. The company's pipeline targets hematology, cardiovascular, and rare diseases. Key programs include Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. Additionally, Zerlasiran (SLN360) targets cardiovascular disease associated with elevated lipoprotein(a). The portfolio also includes preclinical candidates SLN312 for dyslipidemia, SLN365 for hypercholesterolemia, and SLN098 for obesity. Silence Therapeutics was formerly known as SR Pharma plc before rebranding in May 2007.

Silence Therapeutics plc is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol SLN. Its securities trade in US Dollars (USD). The company is headquartered in London, United Kingdom, but its shares are traded on a US exchange, providing access to American investors.

Silence Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing siRNA-based therapeutics to silence disease-causing genes. This places it among firms that use cutting-edge genetic approaches to address unmet medical needs in areas like hematology, cardiovascular, and rare diseases.

Silence Therapeutics plc is headquartered in London, United Kingdom. The company was incorporated in 1994 and was formerly known as SR Pharma plc before rebranding to Silence Therapeutics in May 2007. It operates primarily in the US region (as indicated by its Nasdaq listing) but serves a global market with its siRNA-based drug development programs.

Silence Therapeutics has a pipeline of siRNA-based product candidates targeting various diseases. The most advanced is Divesiran (SLN124), currently in Phase 2 development for polycythemia vera, a blood disorder. Zerlasiran (SLN360) is in development for cardiovascular disease associated with elevated lipoprotein(a). Other candidates include SLN548 for complement-mediated renal diseases, SLN312 for dyslipidemia, SLN365 for hypercholesterolemia, and SLN098 for obesity. These programs reflect the company's focus on hematology, cardiovascular, and rare diseases.